OSE Immunotherapeutics Stock

Equities

OSE

FR0012127173

Biotechnology & Medical Research

Real-time Euronext Paris 07:44:46 2024-06-21 EDT 5-day change 1st Jan Change
6.12 EUR -3.01% Intraday chart for OSE Immunotherapeutics -2.70% +42.99%

Financials

Sales 2024 * 53.43M 57.09M 78.16M Sales 2025 * 79.67M 85.14M 117M Capitalization 137M 147M 201M
Net income 2024 * 17M 18.17M 24.87M Net income 2025 * 48M 51.29M 70.22M EV / Sales 2024 * 2.82 x
Net Debt 2024 * 13.66M 14.6M 19.98M Net cash position 2025 * 35.45M 37.88M 51.86M EV / Sales 2025 * 1.28 x
P/E ratio 2024 *
9.61 x
P/E ratio 2025 *
2.6 x
Employees 55
Yield 2024 *
-
Yield 2025 *
-
Free-Float 72.4%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on OSE Immunotherapeutics

1 day-3.01%
1 week-2.70%
Current month-25.73%
1 month-15.70%
3 months+26.84%
6 months+49.27%
Current year+42.99%
More quotes
1 week
5.71
Extreme 5.71
6.45
1 month
5.71
Extreme 5.71
8.63
Current year
3.12
Extreme 3.115
8.63
1 year
2.71
Extreme 2.705
8.63
3 years
2.71
Extreme 2.705
13.68
5 years
2.71
Extreme 2.705
15.80
10 years
2.70
Extreme 2.7
15.80
More quotes
Managers TitleAgeSince
Founder 69 04-11-16
Chief Executive Officer 42 16-05-30
Director of Finance/CFO - 16-04-30
Members of the board TitleAgeSince
Founder 69 04-11-16
Director/Board Member 66 23-06-21
Chairman 68 16-05-30
More insiders
Date Price Change Volume
24-06-21 6.12 -3.01% 56 134
24-06-20 6.31 +7.86% 299,420
24-06-19 5.85 -4.72% 119,031
24-06-18 6.14 -0.16% 116,069
24-06-17 6.15 -2.23% 231,189

Real-time Euronext Paris, June 21, 2024 at 07:44 am

More quotes
OSE Immunotherapeutics develops first-in-class assets in immuno-oncology (IO) & immuno-inflammation (I&I). The Company's current well-balanced first-in-class clinical pipeline includes: - Tedopi® (lung cancer vaccine): positive Phase 3 results in NSCLC. Other Phase 2 trials of Tedopi® in combination are ongoing in solid tumors; - OSE-279 (anti-PD1): Phase 1/2 positive results in solid tumors; - OSE-127/Lusvertikimab (humanized monoclonal antibody antagonist of IL-7 receptor): Phase 2 in Ulcerative Colitis. Preclinical research in leukemia; - FR-104/VEL-101 (anti-CD28 mAb): partnership with Veloxis in transplantation; Phase 1/2 in renal transplant (CHU Nantes); - BI 765063/BI 770371 (anti-SIRP? mAb): partnership with Boehringer Ingelheim in advanced solid tumors; - OSE-230 (ChemR23 agonist mAb): partnership with AbbVie in chronic inflammation. OSE Immunotherapeutics expects to generate further significant value from its three proprietary drug discovery platforms: - Pro-resolutive mAb platform focused on targeting and advancing inflammation resolution in I&I; - Myeloid Checkpoint platform focused on optimizing the therapeutic potential of myeloid cells in IO; - Cytokine platform focused on leveraging the Cis-Delivery of cytokine in IO and I&I.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
6.31 EUR
Average target price
7.15 EUR
Spread / Average Target
+13.31%
Consensus